Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin; Nordilet) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea

Next Previous
X
Search
Trial Profile

A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin; Nordilet) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatropin (Primary)
  • Indications Short stature
  • Focus Registrational; Therapeutic Use
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 04 Apr 2016 Primary endpoint (Height velocity (Ht-V) after 6 months treatment) has been met, according to results presented at The 98th Annual Meeting of the Endocrine Society.
    • 04 Apr 2016 Results assessing efficacy of recombinant human growth hormone (hGH) (Norditropin; Nordilet) presented at The 98th Annual Meeting of the Endocrine Society.
    • 18 Feb 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top